IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio (Nasdaq: INAB) granted one new employee a stock option covering 4,000 common shares on November 2, 2026.

Rhea-AI Summary

IN8bio (Nasdaq: INAB) granted one new employee a stock option covering 4,000 common shares on November 2, 2026. The Compensation Committee approved the nonqualified option under the company’s 2026 Inducement Plan as an inducement to enter employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

The option vests over four years: 25% on the first anniversary of the employee’s start date, followed by 36 equal monthly installments. Each vesting date requires continued employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Stock option covering 4,000 common shares creates potential dilution if exercised, subject to vesting.

Key Figures

Option shares: 4,000 shares Vesting period: Four years Initial vesting: 25% +1 more

Option shares

4,000 shares

Option granted to one employee

Vesting period

Four years

Stock option vesting schedule

Initial vesting

25%

Vests on the employee’s first anniversary

Subsequent vesting

36 equal monthly installments

Remainder of the option, subject to continued employment

Historical Context

1 past event · Latest: Oct 06

1 event

1. Oct 06

   Inducement grant

   24h Move

   +0.7%

   Earlier award under the same plan covered 60,000 shares and used a four-year vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nonqualified stock option, allogeneic, autologous, γδ t cell

4 terms

nonqualified stock option financial

"granted one employee a nonqualified stock option"

A nonqualified stock option (NQSO) is a company grant that gives an individual the right to buy shares at a set price but does not meet special tax rules for incentive stock options; when exercised the difference between the market price and the exercise price is treated as ordinary income for the recipient and as a tax-deductible expense for the company. It matters to investors because NQSOs affect an employee’s after-tax proceeds, the company’s reported expenses, and potential share dilution—think of it like a cash bonus that converts into stock but is taxed as regular pay when you take it.

allogeneic medical

"an allogeneic γδ T cell candidate"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

autologous medical

"an autologous genetically modified γδ T cell candidate"

Autologous describes a medical product or treatment made from a patient’s own cells or tissues rather than from a donor. For investors, autologous approaches matter because they can lower the risk of immune rejection and improve effectiveness, but they often require individualized manufacturing, complex logistics, and higher per-patient costs—factors that affect scalability, pricing, and regulatory hurdles in healthcare businesses.

γδ t cell medical

"developing γδ T cell and γδ T cell engager product candidates"

A γδ T cell is a specialized type of white blood cell that helps the immune system spot and respond to damaged, infected, or cancerous cells; unlike most T cells that use one kind of receptor, γδ T cells use a different receptor that lets them react quickly to a wider variety of threats. Investors care because these cells are a focus of experimental immunotherapies and diagnostics—like a versatile security team being turned into a product—so advances, trial results, or setbacks can materially affect biotech companies’ pipelines and valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of November 2, 2026, as an inducement material to the new employee entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of such employee’s start date, with the remainder of the option vesting in 36 equal monthly installments thereafter, subject to continued employment on each vesting date.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does IN8bio’s employee inducement option cover?

The nonqualified stock option covers 4,000 common shares for one new employee. Its grant date was November 2, 2026, under the company’s 2026 Inducement Plan.

When does IN8bio’s November 2026 inducement option vest?

The option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder in 36 equal monthly installments thereafter. Vesting requires continued employment on each vesting date.